Study to Evaluate if the Addition of r-hLH (Luveris®) to FSH From Day 8 of Ovarian Stimulation is Able to Decrease Total FSH Dose and to Improve Cycle Outcome in Infertile Women Undergoing ART, Who Required High FSH Dose in a Previous Cycle

NCT01071200 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

133

Enrollment

INDUSTRY

Sponsor class

Conditions

Reproductive Techniques, Assisted

Interventions

DRUG: Recombinant human Follicle Stimulating Hormone (r-hFSH) and Recombinant human Luteinizing Hormone (r-hLH)
DRUG: r-hFSH

Sponsor

Merck KGaA, Darmstadt, Germany

Collaborators

[object Object]